menu
    • menu
    [{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SPL7013","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SPL7013","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"SPL7013","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"SPL7013","moa":"polymers: dendrimers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"Starpharma","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpharma","amount2":0.56999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Starpharma \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma \/ Genentech"}]

    Find Clinical Drug Pipeline Developments & Deals by Starpharma

    Menu

    Starpharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Genentech

                            Deal Size : $569.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Starpharma Announces a Collaboration and License Agreement with Genentech

                            Details : Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $5.5 million

                            September 22, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Genentech

                            Deal Size : $569.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Starpharma Signs New DEP Agreement With MSD

                            Details : Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 10, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabazitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Starpharma Releases Positive DEP® phase 2 Interim Results in Prostate Cancer

                            Details : The positive interim results are particularly significant given all patients in this cohort had late-stage prostate cancer and had failed multiple anti-cancer treatments (including taxanes), in addition to surgeries and radiation, prior to entering the D...

                            Product Name : DEP Cabazitaxel

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 27, 2021

                            Lead Product(s) : Cabazitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabazitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US Patent Issued For DEP® Cabazitaxel Nanoparticle

                            Details : The composition of matter patent covers a DEP® dendrimer conjugated to multiple cabazitaxel drug molecules via a particular releasable linker. DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®...

                            Product Name : DEP Cabazitaxel

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 15, 2021

                            Lead Product(s) : Cabazitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model

                            Details : Viraleze administered nasally reduced viral load by more than 99.9% in the lungs and trachea of animals challenged with the SARS-CoV-2 virus, compared to saline-control.

                            Product Name : Viraleze

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2021

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VIRALEZE™ Now Launched by Lloyds Pharmacy in the UK

                            Details : Starpharma has launched its antiviral nasal spray VIRALEZE™ into the UK via a large national pharmacy chain to support COVID-19 efforts. VIRALEZE™ was developed, manufactured and registered by Starpharma.

                            Product Name : Viraleze

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2021

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Starpharma Signs DEP® ADC Research Agreement with MSD

                            Details : Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 12, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Starpharma Provides Development Update on Spl7013 Nasal Spray for Covid-19

                            Details : Based on discussions with regulators, the company expects to be able to expedite approval of a SPL7013 nasal spray by leveraging existing nonclinical and clinical data of Starpharma’s currently approved and marketed products.

                            Product Name : Viraleze

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 25, 2020

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Starpharma to Develop COVID-19 Treatment

                            Details : Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19.

                            Product Name : Viraleze

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2020

                            Lead Product(s) : Astodrimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Starpharma

                            Australia arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

                            Details : Metronidazole is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vaginosis, Bacterial.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 12, 2014

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth